Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics Inc. (Nasdaq: CMPX) advances novel antibody therapies targeting cancer's complex biology through its clinical-stage pipeline. This dedicated news center provides investors and researchers with essential updates on oncology developments, trial milestones, and scientific breakthroughs.
Access timely reports on bispecific antibody programs, including Tovecimig (CTX-009) for biliary tract cancers and CTX-471's CD137 agonist mechanism. Track regulatory progress across multiple indications and discover partnership announcements leveraging Compass' StitchMabs platform technology.
Our curated news collection serves as your primary source for:
- Phase 1-3 clinical trial updates
- FDA submissions and international regulatory milestones
- Peer-reviewed research publications
- Strategic collaborations in immuno-oncology
Bookmark this page for real-time insights into Compass' work on angiogenesis modulation and tumor microenvironment targeting. Monitor biomarker-driven developments that could shape next-generation cancer treatments.
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced its participation in the H.C. Wainwright BioConnect Investor Conference in New York City on May 2, 2023. The event will feature a Fireside Chat scheduled for 10 AM ET. A webcast link for the presentation is available online. Following the live event, a replay will be archived for 90 days on Compass's Events page. Compass Therapeutics is focused on developing proprietary antibody-based therapeutics targeting oncology, aiming to engage multiple critical biological pathways for effective anti-tumor responses. Founded in 2014 and based in Boston, the company is dedicated to advancing its clinical pipeline with novel product candidates.
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the Stifel 2023 Virtual Targeted Oncology Days, scheduled for April 25 – 26, 2023. The company will engage in a fireside chat on April 26 at 11 AM ET, which can be accessed via a webcast. The corporate presentation will be archived for 90 days on their Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics aimed at treating various human diseases. Central to their research is the relationship between angiogenesis, the immune system, and tumor growth. Their innovative pipeline targets critical biological pathways to enhance anti-tumor responses. For further details, visit www.compasstherapeutics.com.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the Cantor Fitzgerald Future of Oncology Symposium scheduled for April 3-5, 2023. The company will present on April 4 at 8:15 AM ET. Compass Therapeutics is developing proprietary antibody-based therapeutics targeting various human diseases, emphasizing the interplay between angiogenesis, the immune system, and tumor growth. Their innovative pipeline aims to address critical biological pathways for effective anti-tumor responses, advancing both standalone therapies and combination strategies. Founded in 2014, the company is headquartered in Boston, Massachusetts.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
